Navigation Links
The FDA Releases a Public Health Statement on Metal-on-Metal Hip Implants
Date:2/17/2011

RED BANK, N.J., Feb. 17, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) posted a public health communication this week about metal-on-metal hip components to notify the public of the concerns on the use of metal-on-metal hip components used in total hip arthroplasty (THA).  

The information on the F.D.A. website, notifies people of the symptoms which include "hip/groin pain, local swelling, numbness or changes in your ability to walk."

According to the site, "Metal-on-metal hip implants, like other types of hip implants, are known to have adverse events including infection and joint dislocation. There are some case reports of the metal particles causing a reaction around the joint, leading to deterioration of the tissue around the joint, loosening of the implant and failure of the device, as well as some of the symptoms described above. In addition, some metal ions from the implant may enter into the bloodstream. There have been a few recent case reports of patients with metal-on-metal hip implants developing a reaction to these ions and experiencing medical problems that might have been related to their implants, including effects on the nervous system, heart and thyroid gland."

The statement comes months after DePuy Orthopaedics, a subsidiary of Johnson & Johnson, issued a recall on their ASR line of hip replacement devices which were metal-on-metal hip components.  After hundreds of patients complained to the F.D.A., stemming back to 2008, the F.D.A. finally released a statement to the public.

"We are discovering that there are multiple clients throughout the U.S. who need surgery as a result of injuries they suffered since the initial hip replacement surgery," said Christopher Placitella, partner at the law firm of Cohen, Placitella & Roth. "They received DePuy ASR hip replacement systems and subsequently experienced significant pain. As a result, these DePuy ASR implants now require removal at significant expense.  Accordingly, we are currently exploring all legal options on behalf of clients."

According to Chris Placitella, anyone who has received a hip replacement in the U.S. after July 2003 may have received a DePuy ASR device that contains defects.

If you have suffered injury from the ASR hip replacement system, please fill out the form or contact us immediately at lawyers@cprlaw.com or give us a call at 1-888-375-7600.


'/>"/>
SOURCE DePuy Hip Recall Lawyers
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... the U.S. Food and Drug Administration (FDA) has notified the ... to its Zhejiang, China manufacturing facility ... "The successful clearance of the Warning Letter related to our ... a measure of the progress we have made in our ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... ... , is pleased to announce a new online course entitled Personal & ... practical insights and evidence-based strategies for achieving optimal well-being and teaches students how ...
(Date:6/20/2017)... ... , ... Kenneth Mayer, MD, has been appointed a new Editor-in-Chief of the ... the JIAS Editorial Board in 2016, has co-authored more than 800 peer-reviewed publications. Among ... and Co-Chair of The Fenway Institute, a member of the US President’s Emergency ...
(Date:6/20/2017)... York, NY (PRWEB) , ... June 20, 2017 , ... ... today their continued expansion and success in the clinical trials market. Similar to its ... a track record in the clinical trials marketplace by proving the value of eVisits ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju R. Kejriwal ... leading-edge care, whether or not they have a referral. Dr. Kejriwal offers state-of-the-art ... laser, she targets bacteria and damaged tissue without affecting the surrounding tissue. This ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... (AHN) Jefferson Hospital is providing physicians with advanced capabilities for diagnosing and treating ... than traditional MRIs, enabling doctors to get a more accurate look inside the ...
Breaking Medicine News(10 mins):